Quarterly results round-up: Alere and Qiagen slash guidance after challenging Q2
This article was originally published in Clinica
Diagnostics firm Alere has cut its full-year financial guidance to $2.50-2.60 per diluted share, after being hit by lower-than-expected revenues from its health management business. Sales in the unit were down to $135.6m in the second quarter, compared to $149.8m during the same period last year, due to problems including reduced state government spending levels, which the company expects to persist for the rest of the year. Alere had previously predicted earnings of around $2.75 per share.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.